Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial

Further to the patent expiry of Neupogen® (Amgen filgrastim), Hospira has developed a biosimilar filgrastim (Nivestim™) that may offer a clinically effective alternative for multiple hematologic and oncologic indications. Here results are reported from a phase I trial, primarily designed to compare...

Descripción completa

Detalles Bibliográficos
Autores principales: Waller, Cornelius F., Bronchud, Miguel, Mair, Stuart, Challand, Rodeina
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2010
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2924967/
https://www.ncbi.nlm.nih.gov/pubmed/20567823
http://dx.doi.org/10.1007/s00277-010-0973-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2924967/
https://www.ncbi.nlm.nih.gov/pubmed/20567823
http://dx.doi.org/10.1007/s00277-010-0973-6

Ejemplares similares